Makoto Katsumata

Director, Animal Models Core Facility

Send an Email

Research Office:





Makoto Katsumata

Director, Animal Models Core Facility

The research of Makoto Katsumata, PhD, focuses on targeted cancer therapy and development of animal models to study molecular pathways involved in various human diseases. He is one of the pioneers who developed fundamental technology in targeted therapy of Her2/neu expressing cancer.

  • Member, Society for Developmental Biology
  • Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol. 2009 Aug;87(1):1-11.
  • Katsumata M, Drebin JA, Greene MI. Trastuzumab in breast cancer. N Engl J Med. 2006 Feb 9;354(6):640-4; author reply 640-4.
  • Greeley SA, Katsumata M, Yu L, Eisenbarth GS, Moore DJ, Goodarzi H, Barker CF, Naji A, Noorchashm H. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med. 2002 Apr;8(4):399-402.
  • Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Jolicoeur P, Greene MI. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med. 1995 Jul;1(7):644-8.
  • Katsumata M, Siegel RM, Louie DC, Miyashita T, Tsujimoto Y, Nowell PC, Greene MI, Reed JC. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80.

Show moreShow less

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to Makoto Katsumata